NASDAQ$AUPH
Aurinia Pharmaceuticals Inc. · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Aurinia Pharmaceuticals reported Q3 2025, revenue of $85M, net income of $32M, diluted EPS of $0.23.
For Q3 2025, Aurinia Pharmaceuticals reported revenue of $85M, net income of $32M, diluted EPS was $0.23. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.
- Revenue $85M.
- Net income $32M.
- Diluted EPS $0.23.
Headline financials
Revenue & EPS history
Aurinia · Revenue · Quarterly
$73.5M
Revenue by segment
Aurinia · $40.8M total across 1 segment · Q3 2023
- Net Product Sales$40.8M+59.9%100.0%
Forward guidance
The release discusses Aurinia Pharmaceuticals's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- Aurinia Pharmaceuticals cites demand and execution supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
-1.4%
Avg return
Earnings day
-0.3%
Avg return
5 days after
+4.6%
Avg return
30 days after
41%
18 / 44 earnings
Positive
+25.7%
Q2 2021
Best reaction
-32.3%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -7.0% | -1.6% | -2.6% | |
| Q4 2025 | -3.1% | -1.9% | -1.1% | |
| Q3 2025 | -3.4% | +8.5% | +8.1% | |
| Q1 2025 | +1.8% | +2.4% | +1.1% | |
| Q4 2024 | -5.0% | +1.6% | +4.3% | |
| Q3 2024 | +10.6% | +11.4% | +18.8% | |
| Q2 2024 | -6.5% | -4.4% | +15.8% | |
| Q1 2024 | -1.9% | -1.5% | +4.2% | |
| Q4 2023 | -26.6% | -29.9% | -35.1% | |
| Q3 2023 | +15.4% | +16.3% | +27.1% | |
| Q2 2023 | -3.1% | -4.1% | -6.6% | |
| Q1 2023 | -1.1% | -4.2% | -18.4% | |
| Q4 2022 | +7.9% | +7.9% | +31.8% | |
| Q3 2022 | -32.3% | -29.3% | -33.0% | |
| Q2 2022 | -1.5% | -4.4% | -15.1% | |
| Q1 2022 | +7.1% | +24.9% | +35.2% | |
| Q4 2021 | -26.0% | -34.9% | -23.7% | |
| Q3 2021 | -0.3% | -2.1% | -41.7% | |
| Q2 2021 | +25.7% | +32.9% | +52.9% | |
| Q1 2021 | -17.3% | -8.5% | +1.7% | |
| Q4 2020 | +1.4% | +0.7% | -12.9% | |
| Q3 2020 | -4.0% | -3.1% | +7.3% | |
| Q2 2020 | -1.3% | -2.4% | -0.8% | |
| Q1 2020 | -2.3% | -3.7% | -11.7% | |
| Q4 2019 | -9.0% | -16.9% | -22.1% | |
| Q3 2019 | -2.4% | +13.6% | +245.4% | |
| Q2 2019 | -7.5% | -7.5% | -6.4% | |
| Q1 2019 | +4.3% | +8.9% | +3.6% | |
| Q4 2018 | +8.9% | +3.2% | +0.6% | |
| Q3 2018 | +1.3% | -6.5% | +9.7% | |
| Q2 2018 | +0.4% | -0.9% | +0.4% | |
| Q1 2018 | +7.3% | +20.3% | +5.7% | |
| Q4 2017 | +6.5% | +0.8% | +1.5% | |
| Q3 2017 | -11.0% | -8.5% | -15.3% | |
| Q2 2017 | +1.7% | +4.4% | +13.3% | |
| Q1 2017 | -4.6% | -6.6% | -22.3% | |
| Q4 2016 | +18.7% | -1.5% | -11.0% | |
| Q3 2016 | +1.2% | -0.8% | +13.3% | |
| Q2 2016 | +4.9% | +17.7% | -41.4% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | -4.8% | — | — | |
| Q2 2015 | -4.0% | — | — | |
| Q4 2014 | +4.9% | — | — | |
| Q3 2014 | -7.2% | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro